Group 1 - Asian share markets experienced a significant selloff, particularly in drugmakers and furniture makers, following the announcement of new tariffs by U.S. President Donald Trump [1][5] - The new tariffs include a 100% duty on branded drugs and a 25% tariff on heavy-duty trucks, effective from October 1, which could impact global drugmakers and manufacturers [1][4] - Companies like Paccar-owned Peterbilt and Kenworth, as well as Daimler Truck-owned Freightliner, may benefit from the tariffs on heavy-duty trucks [4] Group 2 - The Trump administration's trade deals with Japan, the EU, and the UK include provisions that cap tariffs for specific products, which may limit the impact of the new tariffs on certain sectors [3] - Global drugmakers are proactively increasing their U.S. manufacturing capacity and domestic inventory in response to the new tariffs [3] - The market is currently pricing in approximately 39 basis points of easing by December, reflecting a shift in expectations regarding U.S. interest rate cuts due to tariff-related inflation concerns [6]

Emerging-market assets drop as the fresh round of US tariffs including a 100% duty on branded or patented pharmaceuticals hurt sentiment https://t.co/JRdoOw9UR0 ...

The S&P At around 9:52 AM, Sensex traded 334 pts or 0.40% lower at 80,824, whereas Nifty50 slipped 92 pts of 0.37% to 24,798.On the 30-stock Sensex, shares of Asian Paints, Tech Mahindra, Pharma stocks were the hardest hit, with the Nifty Pharma index dropping 2.3% as all constituents traded lower. Sun Pharma tumbled 5% to a 52-week low, while Live EventsThe selloff comes as the U.S. accounts for just over a third of India’s pharmaceutical exports, largely consisting of low-cost generic drugs. Shipments to ...

Core Viewpoint - Shares of Asian drugmakers experienced a decline following U.S. President Donald Trump's announcement of potential 100% tariffs on imports of branded pharmaceuticals starting October 1, contingent upon the establishment of U.S. manufacturing plants by their producers [1] Group 1 - The announcement by President Trump poses a significant threat to Asian drugmakers, as it could lead to increased costs and reduced competitiveness in the U.S. market [1] - The tariffs are aimed at encouraging pharmaceutical companies to invest in domestic manufacturing, which could reshape the industry landscape [1] - The potential implementation of these tariffs may lead to a broader impact on global supply chains and pricing strategies within the pharmaceutical sector [1]

By Gregor Stuart Hunter and Andrew Silver SINGAPORE/SHANGHAI (Reuters) -Shares of U.S. and European pharmaceutical firms were little changed on Friday, while Asian drugmakers declined, after President Donald Trump announced 100% tariffs on branded drugs imported by firms that are not building plants in the U.S. Analysts said the move was widely expected and unlikely to materially hit the industry, given that most drugmakers have pledged billions of dollars in U.S. manufacturing investments. The condit ...

25 Sep 2025 11:12:18 ET │ 48 pages Global Economic Outlook & Strategy Tariffs & Global Resilience —Waiting for Another Shoe to Drop CITI'S TAKE Global growth remains on a solid trajectory. The economy has cooled a notch, as tariff-related uncertainty has restrained spending, but activity has held up surprisingly well. All told, growth looks to have run at 2.6% during H1, down only slightly from last year. This performance is broadly a reprise of the past two years—and the global economy continues to defy ou ...

Group 1 - President Trump announced new tariffs set to begin on October 1, including 100% duties on imported branded or patented pharmaceuticals, 25% tariffs on heavy-duty trucks, and 50% tariffs on kitchen cabinets [1] - The rationale behind these tariffs is to combat the "flooding" of these products into the U.S. from other countries, which is deemed an unfair practice that threatens national security and domestic manufacturing [2] - The decision to raise tariffs appears unaffected by rising inflation rates, with the consumer price index increasing by 3.1% in August, and significant price hikes in the "food at home" category [3]

Group 1 - Wall Street indexes experienced gains on Friday but still recorded a loss for the week, with consumer spending supporting longer-dated Treasury yields and gold prices rising due to steady inflation readings [1][3] - Consumer spending increased slightly more than expected in August, while the inflation rate rose to 2.7% from 2.6% in July, aligning with economists' expectations [1] - Analysts noted that some companies managed to mitigate price pressures by stockpiling in anticipation of tariffs, but upcoming corporate earnings releases will be a significant test for many firms [2] Group 2 - The Dow Jones Industrial Average rose by 0.65%, the S&P 500 increased by 0.59%, and the Nasdaq Composite was up by 0.44% [3] - Individual stocks reacted to new White House tariffs, with Paccar gaining 5% and Eli Lilly rising 1.5% [3] - Richmond Fed Bank President expressed low confidence in inflation forecasts due to ongoing tariff impacts on the economy [3] Group 3 - The personal consumption expenditures index is a key component of the Federal Reserve's inflation outlook, with U.S. Treasury yields showing minimal movement after data release [5] - The yield on benchmark U.S. 10-year notes rose by 0.7 basis points to 4.181%, while the 30-year bond yield increased by 0.5 basis points to 4.7576% [5] - Gold prices, typically benefiting from lower interest rates, held onto recent gains, with spot prices quoted at $3,766.25 an ounce, up by 0.46% [6] Group 4 - Investors currently estimate an 89.8% probability of a rate cut in October and a 67% chance of another cut in December, according to the CME FedWatch Tool [7]

Breaking: Trump said the U.S. will impose 100% tariffs on drugs from companies that aren't building plants in America https://t.co/utIEYoi9KG ...

Core Viewpoint - Tariffs on drugs will be imposed on companies that do not have manufacturing plants in the U.S. [1] Group 1 - The new tariffs aim to incentivize pharmaceutical companies to establish production facilities within the United States [1] - Companies without U.S. plants will face increased costs, potentially affecting their pricing strategies and market competitiveness [1] - This policy is part of a broader initiative to boost domestic manufacturing and reduce reliance on foreign production [1]